You are here

Development and in vitro validation of therapy for mucopolysaccharidosis III

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41NS089061-01
Agency Tracking Number: R41NS089061
Amount: $224,602.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 105
Solicitation Number: PA12-100
Timeline
Solicitation Year: 2013
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-01
Award End Date (Contract End Date): 2016-08-31
Small Business Information
200 16TH ST, #3D, Brooklyn, NY, 11215-8441
DUNS: 078416746
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 SEAN EKINS
 (215) 687-1320
 ekins@collaborations.com
Business Contact
 JILL WOOD
Phone: (347) 831-0246
Email: jw.mps3c@gmail.com
Research Institution
 PHOENIX NEST, INC.
 200 16TH ST, #3D
BROOKLYN, NY, 11215-8441
 Domestic nonprofit research organization
Abstract
DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays important structural and functional roles in the brain and elsewhere Each type of MPS III A through D is due to deficiency of a different enzyme in the HS breakdown pathway We now propose to develop an enzyme replacement treatment for MPS III that will ameliorate or reverse the catastrophic and fatal neurologic decline caused by this disease As the symptoms of MPS III are largely localized to the brain any effective MPS III treatment must therefore gain access to the brain Therefore our strategy proposes to deliver recombinant human alpha N acetylglucosamine sulfatase rhGNS intrathecally into the spinal fluid to effectively treat the underlying causes of the neurologic symptoms that dominate MPS III pathology Our collaborative team includes Dr Patricia Dickson and her colleagues at the Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center Dr Dickson is an expert in the mucopolysaccharidoses with specific expertise in the bench to bedside development of intrathecal enzyme replacement therapy Encouraging preliminary data from the Dickson lab shows robust expression of rhGNS in Chinese hamster ovary cells that could make scale up feasible Building on this prior experience with developing treatments for other MPS diseases combined with initial preliminary data that for the first time suggests a treatment for MPS III might be practical we now propose two AIMS for this phase I STTR to determine whether further development of our therapeutic approach to MPS III is feasible and justified by the strength of empiric data Aim Determine whether rhGNS has properties favorable for a recombinant enzyme therapy Aim Determine whether rhGNS can enter cells reach lysosomes and reduce HS accumulation Our long term objective is to produce an effective recombinant enzyme therapy for MPS III as rapidly and efficiently as possible Upon successful achievement of Aims and will initiate proposed a Phase II project which will access the efficacy pharmacokinetics and toxicity studies in animal studies PUBLIC HEALTH RELEVANCE Our project has the potential to develop a new treatment for a fatal neurodegenerative disorder of childhood While rare the condition causes substantial disability and death as well as a large economic emotional and social burden to affected families

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government